Anti-Leukocyte Adhesion For The Mitigation Of Potential Adverse Events Caused By CD3-Specific Binding Domains

Abstract The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directin...

Full description

Saved in:
Bibliographic Details
Main Authors Nagorsen, Dirk, Kufer, Peter, Hoffmann, Patrick, Klinger, Matthias, Scheele, Juergen, Zugmaier, Gerhard, Naegele, Virginie, Dopfer, Elaine-Pashupati
Format Patent
LanguageEnglish
Published 13.08.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Abstract The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
Bibliography:Application Number: AU20190200841